MedPath

Off-the-Shelf NK Immunotherapy Shows Promise in B-Cell NHL Treatment

5 years ago2 min read
Early results from a phase 2 trial (NCT03019640) have shown promising outcomes for patients with B-cell non-Hodgkin lymphoma (NHL) undergoing treatment with cord blood-derived natural killer (NK) immunotherapy alongside high-dose chemotherapy and autologous stem cell transplant (ASCT). The trial focused on the potential of this novel cellular therapy in inducing early antitumor responses.
Patients aged 15 to 70 with B-cell NHL, excluding primary central nervous system lymphoma, were eligible for the study provided they had adequate end-organ function, an ECOG performance status of 0 or 1, and prior apheresis of ≥2 x 10^6 CD34+ cells/Kg. The treatment regimen included intravenous carmustine, etoposide, cytarabine, melphalan, and oral lenalidomide, with CD20-positive patients also receiving rituximab.
Cord blood-derived expanded allogeneic NK cells were administered intravenously five days prior to ASCT, followed by daily subcutaneous filgrastim starting five days post-ASCT. The study's primary endpoint was 30-day treatment-related mortality, with secondary endpoints including relapse-free survival (RFS), overall survival, and NK cell persistence.
Among the 19 treated patients, the median age was 60 years, with the majority being male and having diffuse large B-cell lymphoma (DLBCL). Response assessments through PET at ASCT showed a complete response in 78.9% of patients, partial response in 15.8%, and progressive disease in 5.3%. The study found that cord blood-derived NK cells were expanded significantly and maintained high viability, with NK cells detectable in the peripheral blood for a mean of 2 weeks.
At a median follow-up of 18 months, the RFS rate was 68%, and the overall survival rate was 84%. The study concluded that expanded and highly purified cord blood-derived NK immunotherapy is safe and shows promise in combination with high-dose chemotherapy and ASCT for treating B-cell NHL.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.